Insulet (Nasdaq: PODD ) reported earnings on Aug. 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Insulet met expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share dropped.
Gross margins dropped, operating margins improved, net margins increased.
Insulet notched revenue of $51.0 million. The 15 analysts polled by S&P Capital IQ expected a top line of $51.8 million on the same basis. GAAP reported sales were 58% higher than the prior-year quarter's $32.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.30. The 15 earnings estimates compiled by S&P Capital IQ predicted -$0.25 per share. GAAP EPS were -$0.30 for Q2 versus -$0.42 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 43.8%, 130 basis points worse than the prior-year quarter. Operating margin was -20.6%, 1,580 basis points better than the prior-year quarter. Net margin was -28.4%, 3,190 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $55.8 million. On the bottom line, the average EPS estimate is -$0.21.
Next year's average estimate for revenue is $215.9 million. The average EPS estimate is -$0.91.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 69 members out of 114 rating the stock outperform, and 45 members rating it underperform. Among 39 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 25 give Insulet a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Insulet is outperform, with an average price target of $23.04.
- Add Insulet to My Watchlist.